Q4 2024 Regeneron Pharmaceuticals Inc Earnings Call
Marion McCourt; Executive Vice President - Commercial; Regeneron Pharmaceuticals Inc. Christopher Fenimore; Chief Financial Officer, Senior Vice President - Finance; Regeneron Pha ...
Regeneron projects EYLEA HD growth with new approvals and prefilled syringe launch in 2025
EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these developments ...
Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the ...
Regeneron reports Q4 non-GAAP EPS $12.07, consensus $11.19
Reports Q4 revenue $3.79B, consensus $3.75B. “Regeneron’s (REGN) financial and commercial strength allows for continued investment in our ...
Investing2d
Regeneron shares rise as Q4 earnings top estimates
Regeneron (NASDAQ: REGN )'s flagship eye drug franchise, consisting of EYLEA HD and EYLEA, saw U.S. net sales increase 2% to ...
BioSpace2d
Regeneron Misses on Eylea, Dupixent Sales; Issues First-Ever Dividends
Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...
Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025
Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...
Regeneron's earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...
manilatimes24d
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
"The Regeneron name is synonymous with innovation, brought to life through proprietary technologies and world-class science that produce medicines that make a meaningful impact on patients' lives,” ...
Indiatimes24d
Top 10 highest-paid CEOs in the world from Elon Musk to Sundar Pichai and their annual salary
Leonard Schleifer for Regeneron Pharmaceuticals: $452.9 million Leonard Schleifer is the chief executive of Regeneron Pharmaceuticals, a biopharmaceutical company known for its innovative medicines.
Business Insider24d
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
“The Regeneron name is synonymous with innovation ... that make a meaningful impact on patients’ lives,” said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive ...
India.com21d
Meet world’s highest paid CEOs, wealthier than Mukesh Ambani, Gautam Adani; richest earns a salary of Rs…
The CEO and co-founder of biotech firm, Regeneron, Leonard Schleifer earn and annual salary of $452 million, as per reports. Reed Hastings, the co-founder and executive chairman of streaming giant ...